Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition, ...
A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...
For over 50 years, Nasdaq has been a leader in the exchange space through our technology innovations. We built our IPO process in partnership with the investment banking community, ensuring that ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
4d
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from ...
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech ...
MBX plans to list on the Nasdaq under the symbol MBX. The recent flurry of IPOs adds to the sense that the environment for biotechs seeking to go public after a two-year lull, with a pick-up in ...
This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.
2-Year U.S. Treasury Note Continuous Contract $102.805-0.008-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.523 0.133 0.12% 10-Year U.S. Treasury Note Continuous Contract $109.172 0.328 ...
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday U.S. stocks were mostly lower, with the Nasdaq Composite falling more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback